EP1558341A4 - Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers - Google Patents

Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers

Info

Publication number
EP1558341A4
EP1558341A4 EP03783155A EP03783155A EP1558341A4 EP 1558341 A4 EP1558341 A4 EP 1558341A4 EP 03783155 A EP03783155 A EP 03783155A EP 03783155 A EP03783155 A EP 03783155A EP 1558341 A4 EP1558341 A4 EP 1558341A4
Authority
EP
European Patent Office
Prior art keywords
methods
transcription factor
modulating compounds
factor modulating
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03783155A
Other languages
German (de)
English (en)
Other versions
EP1558341A2 (fr
Inventor
Stuart B Levy
Michael N Alekshun
Brent L Podlogar
Kwasi Ohemeng
Atul K Verma
Tadeusz Warchol
Beena Bhatia
Todd Bowser
Mark Grier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Publication of EP1558341A2 publication Critical patent/EP1558341A2/fr
Publication of EP1558341A4 publication Critical patent/EP1558341A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eyeglasses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EP03783155A 2002-11-01 2003-11-03 Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers Withdrawn EP1558341A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42331902P 2002-11-01 2002-11-01
US423319P 2002-11-01
US42591602P 2002-11-13 2002-11-13
US425916P 2002-11-13
PCT/US2003/035205 WO2004041209A2 (fr) 2002-11-01 2003-11-03 Composés modulant le facteur de transcription et méthodes d'utilisation de ces derniers

Publications (2)

Publication Number Publication Date
EP1558341A2 EP1558341A2 (fr) 2005-08-03
EP1558341A4 true EP1558341A4 (fr) 2010-09-08

Family

ID=32314482

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03783155A Withdrawn EP1558341A4 (fr) 2002-11-01 2003-11-03 Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers

Country Status (5)

Country Link
EP (1) EP1558341A4 (fr)
JP (3) JP2006513162A (fr)
AU (1) AU2003291226B2 (fr)
CA (1) CA2504448C (fr)
WO (1) WO2004041209A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1462105A1 (fr) * 2003-03-28 2004-09-29 Procorde GmbH Inhibiteurs spécifiques de l'activation de NF-kB et méthode de traitement des processus inflammatoires des maladies cardiovasculaires
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
EP1742637A4 (fr) * 2004-04-23 2011-06-08 Paratek Pharm Innc Composes de modulation de facteur de transcription et leurs procedes d'utilisation
WO2007016292A2 (fr) * 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Modulateurs de biofilms
WO2008041966A2 (fr) * 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Composés antibactériens à large spectre
US20070178054A1 (en) * 2005-11-09 2007-08-02 Madhyastha Srinivasa Oral antimicrobial composition
AU2007351886A1 (en) * 2006-06-23 2008-10-30 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR20150041172A (ko) * 2006-12-01 2015-04-15 래크리드 인코포레이티드 귀에서 균막을 용해시키기 위한 가수분해 및 산화 효소의 용도
EP2139474A2 (fr) * 2007-03-27 2010-01-06 Paratek Pharmaceuticals, Inc. Composés modulant le facteur de transcription et leurs procédés d'utilisation
EP2000140A1 (fr) 2007-06-05 2008-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation des dérivés de 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine ou de 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine pour la préparation des compositions pharmaceutiques pour le traitement du cancer
WO2010027762A1 (fr) * 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Inhibiteurs indolizine de la production de leukotriènes
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010124097A2 (fr) * 2009-04-22 2010-10-28 Paratek Pharmaceuticals, Inc. Composés modulateurs de facteur de transcription et leurs procédés d'utilisation
WO2011151618A2 (fr) 2010-06-01 2011-12-08 Summit Corporation Plc Composés pour le traitement d'une maladie associée à clostridium difficile
WO2011151617A1 (fr) 2010-06-01 2011-12-08 Summit Corporation Plc Composés pour le traitement d'une maladie associée à clostridium difficile
DK2575968T3 (en) 2010-06-01 2016-05-30 Summit Therapeutics Plc COMPOUNDS FOR THE TREATMENT OF Clostridium difficile-associated disease
WO2011151620A1 (fr) 2010-06-01 2011-12-08 Summit Corporation Plc Composés pour le traitement d'une maladie associée à clostridium difficile
WO2011151619A1 (fr) 2010-06-01 2011-12-08 Summit Corporation Plc Composés destinés au traitement d'une maladie associée à clostridium difficile
US9382226B2 (en) * 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
EP2632257B1 (fr) 2010-10-25 2021-03-31 Vanderbilt University Compositions pour inhiber la capacité d'insectes à détecter des hôtes
MX361688B (es) * 2011-05-02 2018-12-13 Jose Carlos Lapenna Uso de un halógeno-cianoacetamida para fijación y preservación de una muestra biológica.
WO2012154403A2 (fr) * 2011-05-06 2012-11-15 Vanderbilt University Composition destinée à inhiber les perceptions des insectes
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
ITMI20132192A1 (it) * 2013-12-23 2015-06-24 Purisa S R L Composti antimicrobici
WO2016127102A2 (fr) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibition de la germination des spores de clostridium perfringens pour réduire l'entérite nécrotique
BR112017020440A2 (pt) 2015-03-25 2018-07-03 Univ Vanderbilt métodos de interromper o comportamento de percepção de odor em um organismo com um canal de íon de orco e de agonização de um canal de íon de orco, composição para interromper a percepção de odor, e, artigo.
EP3380195B1 (fr) * 2016-01-08 2020-12-09 Institute for Systems Biology Procédés pour identifier des composés antituberculeux
AU2018331456B2 (en) 2017-09-15 2020-10-08 Chinook Therapeutics, Inc. Pyrazolopyrimidinone compounds and uses thereof
WO2021009514A1 (fr) 2019-07-17 2021-01-21 Summit (Oxford) Limited Procédé de préparation de ridinilazole et de formes cristallines de celui-ci
JP7458622B2 (ja) * 2019-09-18 2024-04-01 学校法人東京農業大学 抗生物質耐性微生物の耐性を低下させる物質及び抗生物質耐性微生物の耐性を低下させる方法
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂
CN111166743B (zh) * 2020-01-02 2022-03-22 中国医学科学院医药生物技术研究所 一类含噻唑结构化合物的抗感染用途
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE674202A (fr) * 1964-12-31 1966-06-22
US3325356A (en) * 1965-08-20 1967-06-13 Merck & Co Inc Compositions and method for treating helminthiasis
DE1545718A1 (de) * 1964-12-07 1969-07-10 Ciba Geigy Benzimidazole
US3516999A (en) * 1966-03-26 1970-06-23 Shionogi Seiyaku Kk Benzimidazole derivatives
FR2047462A5 (en) * 1969-05-08 1971-03-12 Hoechst Ag 1-hydroxy-benzimidazole-z-carbpxy acid - amides and esters
DE2109331A1 (de) * 1970-02-27 1971-09-02 Merck & Co Ine , Rahway, N J (V St A) 1 Oxybenzimidazole
US3743738A (en) * 1970-03-05 1973-07-03 Merck & Co Inc Substituted benzimidazoles as anthelmintic agents
CH554892A (de) * 1970-03-05 1974-10-15 Merck & Co Inc Verfahren zur herstellung von 1,5-substituierten oder 1,6substituierten benzimidazolen.
CH556868A (de) * 1970-03-05 1974-12-13 Merck & Co Inc Verfahren zur herstellung von 1-hydroxy-5-(oder 6-)-carbonyl-amino-2-(4'-thiazolyl)-benzimidazolen.
WO2004001058A2 (fr) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Composes modulateurs de facteurs de transcription et procedes d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (fr) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Methode de traitement d'affections epitheliales
JP2001510450A (ja) * 1996-10-23 2001-07-31 ザイモジェネティクス，インコーポレイテッド 骨欠損状態を処置するための組成物および方法
JP2002523459A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545718A1 (de) * 1964-12-07 1969-07-10 Ciba Geigy Benzimidazole
BE674202A (fr) * 1964-12-31 1966-06-22
US3325356A (en) * 1965-08-20 1967-06-13 Merck & Co Inc Compositions and method for treating helminthiasis
US3516999A (en) * 1966-03-26 1970-06-23 Shionogi Seiyaku Kk Benzimidazole derivatives
FR2047462A5 (en) * 1969-05-08 1971-03-12 Hoechst Ag 1-hydroxy-benzimidazole-z-carbpxy acid - amides and esters
DE2109331A1 (de) * 1970-02-27 1971-09-02 Merck & Co Ine , Rahway, N J (V St A) 1 Oxybenzimidazole
US3743738A (en) * 1970-03-05 1973-07-03 Merck & Co Inc Substituted benzimidazoles as anthelmintic agents
CH554892A (de) * 1970-03-05 1974-10-15 Merck & Co Inc Verfahren zur herstellung von 1,5-substituierten oder 1,6substituierten benzimidazolen.
CH556868A (de) * 1970-03-05 1974-12-13 Merck & Co Inc Verfahren zur herstellung von 1-hydroxy-5-(oder 6-)-carbonyl-amino-2-(4'-thiazolyl)-benzimidazolen.
WO2004001058A2 (fr) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Composes modulateurs de facteurs de transcription et procedes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE STEVENS G ET AL: "Derivatives of 1-Hydroxybenzimidazoles and 1-Hydroxyindoles and Their Central Depressant Effects", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM00314A018, vol. 10, no. 2, 1 March 1967 (1967-03-01), pages 211 - 214, XP002980391, ISSN: 0022-2623 *
MINISCI, F. ET AL.: "Addition reaction of nitrile oxides to aromatic nitroso derivatives. A novel synthesis of the benzimidazole ring", TETRAHEDRON LETTERS, no. 12, 1963, pages 785 - 790, XP002594210, ISSN: 0040-4039 *

Also Published As

Publication number Publication date
JP5175316B2 (ja) 2013-04-03
JP2012131813A (ja) 2012-07-12
JP2010235612A (ja) 2010-10-21
CA2504448A1 (fr) 2004-05-21
CA2504448C (fr) 2012-06-19
JP2006513162A (ja) 2006-04-20
AU2003291226B2 (en) 2009-06-04
WO2004041209A3 (fr) 2004-09-30
WO2004041209A2 (fr) 2004-05-21
EP1558341A2 (fr) 2005-08-03
AU2003291226A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
EP1558341A4 (fr) Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers
EP1524974A4 (fr) Composes modulateurs de facteurs de transcription et procedes d'utilisation
IL210693A0 (en) Transcription factor modulating compounds and methods of use thereof
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003295801A8 (en) Modulation of hif1alpha and hif2alpha expression
AU2003303128A1 (en) Inhibitors and methods of use thereof
EP1465615A4 (fr) Derives de bis- enone tricyclique et methodes d'utilisation
AU2003275311A1 (en) Solid micro-perforators and methods of use
EP1521747A4 (fr) Modulateurs de kinase de type recepteur et procedes d'utilisation
HK1079789A1 (zh) 血管靜態毒性試劑及其使用方法
EP1534680A4 (fr) Inhibiteurs de prenylation et leurs methodes de synthese et d'utilisation
AU2003259717A8 (en) Modulators of rabggt and methods of use thereof
AU2003288902A1 (en) Microcapsules and methods of use
EP1567515A4 (fr) Nouveaux composes de lapachone et procedes d'utilisation correspondants
EP1476150A4 (fr) Carboxyfullerenes et procedes d'utilisation de ceux-ci
AU2003275056A1 (en) Novel lapacho compounds and methods of use thereof
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2003265394A1 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
AU2003252026A1 (en) Npc1l1 (npc3) and methods of use thereof
EP1545287A4 (fr) Composes vasoregulateurs et procedes concernant leur utilisation
AU2003287802A1 (en) Palpometer and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050527

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20100809

17Q First examination report despatched

Effective date: 20110222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130601